Development of binational radiation therapy quality indicator reports for prostate cancer treatment using registry data.
quality assurance
radiation oncology
Journal
Journal of medical imaging and radiation oncology
ISSN: 1754-9485
Titre abrégé: J Med Imaging Radiat Oncol
Pays: Australia
ID NLM: 101469340
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
15
07
2022
accepted:
26
09
2022
pubmed:
18
10
2022
medline:
7
12
2022
entrez:
17
10
2022
Statut:
ppublish
Résumé
Quality indicators (QIs) are metrics which seek to allow comparison of clinicians' and institutes' practice to best evidence-based practice. The Australia and New Zealand Prostate Cancer Outcomes Registry (PCOR-ANZ) is a bi-national clinical quality registry with coverage estimated to be over 60% of the men newly diagnosed with prostate cancer. We outline the production and ambition of institute-level QI reports to benchmark performance for radiation therapy in the treatment of prostate cancer. An expert clinician panel was assembled to create a list of candidate QIs based on a comprehensive literature review, and on modified Delphi-method and expert-consensus voting. A separate implementation group-including, clinicians, epidemiologists, data managers and data scientists-employed an evidence- and consensus- based approach to generate an effective QI report designed for automated production and regular distribution to participating institutes. Feedback from the recipient clinicians was sought to enable refinement of these reports. Seven QIs, including three related to post-treatment symptoms, were deemed feasible to analyse with the currently available data. Utilising an existing report template employed for benchmarking of surgical indicators, a novel radiation therapy report was generated using registry data in a secure analytical environment. The first, beta version of these reports have been produced and confidentially distributed. It is planned to automatically generate these reports biannually and iteratively refine them based on the clinician input. QI reports for the treatment of prostate cancer by radiation oncologists have been produced using data from Australia and New Zealand patients. These are being disseminated to institutes on a six-monthly basis allowing comparisons to de-identified peers. The reports aim to facilitate improving patient outcomes, deepen engagement with the radiation oncology community and increase the breadth of PCOR-ANZ coverage. Additional QIs will be included in future iterations of these reports as data matures.
Identifiants
pubmed: 36251627
doi: 10.1111/1754-9485.13481
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1097-1105Subventions
Organisme : Movember Foundation
Informations de copyright
© 2022 Royal Australian and New Zealand College of Radiologists.
Références
Cancer data in Australia: web report Cancer series no. 122, 2020.
Mottet N, van den Bergh RCN, Briers E et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2021; 79: 243-62.
Brundage M, Danielson B, Pearcey R et al. A criterion-based audit of the technical quality of external beam radiotherapy for prostate cancer. Radiother Oncol 2013; 107: 339-45.
Kowalski C, Ferencz J, Albers P et al. Quality assessment in prostate cancer centers certified by the German cancer society. World J Urol 2016; 34: 665-72.
Lee DJ, Barocas DA, Zhao Z et al. Contemporary prostate cancer radiation therapy in the United States: patterns of care and compliance with quality measures. Pract Radiat Oncol 2018; 8: 307-16.
Mainz J. Defining and classifying clinical indicators for quality improvement. International J Qual Health Care 2003; 15: 523-30.
Cionini L, Gardani G, Gabriele P et al. Quality indicators in radiotherapy. Radiother Oncol 2007; 82: 191-200.
Danielson B, Brundage M, Pearcey R et al. Development of indicators of the quality of radiotherapy for localized prostate cancer. Radiother Oncol 2011; 99: 29-36.
Papa N, O'Callaghan M, James E, Millar J. Prostate Cancer in Australian and New Zealand Men: Patterns of care within PCOR-ANZ 2015-2018. Monash University & Movember, March 2021.
Tsiamis E, Millar J, Baxi S et al. Development of quality indicators to monitor radiotherapy care for men with prostate cancer: a modified Delphi method. Radiother Oncol 2018; 128: 308-14.
Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology 2010; 76: 1245-50.
Allaire JJ, Xie Y, McPherson J et al. rmarkdown: Dynamic Documents for R. R package version 2.5, 2020. Available from URL: https://rmarkdown.rstudio.com
Sampurno F, Cally J, Opie JL et al. Establishing a global quality of care benchmark report. Health Informatics J 2021; 27: 14604582211015704.
Kiefe CI, Allison JJ, Williams OD, Person SD, Weaver MT, Weissman NW. Improving quality improvement using achievable benchmarks for physician feedback: a randomized controlled trial. JAMA 2001; 285: 2871-9.
Spiegelhalter DJ. Funnel plots for comparing institutional performance. Stat Med 2005; 24: 1185-202.
Kerkmeijer LGW, Groen VH, Pos FJ et al. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol 2021; 39: 787-96.
Hofman MS, Lawrentschuk N, Francis RJ et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020; 395: 1208-16.
Pryor DI, Martin JM, Millar JL et al. Evaluation of Hypofractionated radiation therapy use and patient-reported outcomes in men with nonmetastatic prostate cancer in Australia and New Zealand. JAMA Netw Open 2021; 4: e2129647.
Sampurno F, Earnest A, Kumari PB et al. Quality of care achievements of the prostate cancer outcomes registry-Victoria. Med J Aust 2016; 204: 319.
Stranne J, Axen E, Franck-Lissbrant I et al. Single institution followed by national implementation of systematic surgical quality control and feedback for radical prostatectomy: a 20-year journey. World J Urol 2020; 38: 1397-411.
Hunter J, Smith C, Delaney GP, Templeman K, Grant S, Ussher JM. Coverage of cancer services in Australia and providers' views on service gaps: findings from a national cross-sectional survey. BMC Cancer 2019; 19: 570.
Harden SV, Chiew KL, Millar J, Vinod SK. Quality indicators for radiation oncology. J Med Imaging Radiat Oncol 2022; 66: 249-57.
Papa N, Bensley JG, Hall K, Evans M, Millar JL. Quantifying the effect email reminders have on patient reported outcome measure returns in a large prostate cancer registry. J Patient Rep Outcomes 2022; 6: 19.
Marcello M, Ebert MA, Haworth A et al. Association between measures of treatment quality and disease progression in prostate cancer radiotherapy: an exploratory analysis from the TROG 03.04 RADAR trial. J Med Imaging Radiat Oncol 2018; 62: 248-55.
Ebert MA, Bulsara M, Haworth A et al. Technical quality assurance during the TROG 03.04 RADAR prostate radiotherapy trial: are the results reflected in observed toxicity rates? J Med Imaging Radiat Oncol 2015; 59: 99-108.
Abrams RA, Winter KA, Regine WF et al. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704-a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 2012; 82: 809-16.
Peters LJ, O'Sullivan B, Giralt J et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol 2010; 28: 2996-3001.
Weber DC, Hurkmans CW, Melidis C et al. Outcome impact and cost-effectiveness of quality assurance for radiotherapy planned for the EORTC 22071-24071 prospective study for head and neck cancer. Radiother Oncol 2014; 111: 393-9.
Weber DC, Tomsej M, Melidis C, Hurkmans CW. QA makes a clinical trial stronger: evidence-based medicine in radiation therapy. Radiother Oncol 2012; 105: 4-8.
Ohri N, Shen X, Dicker AP, Doyle LA, Harrison AS, Showalter TN. Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials. J Natl Cancer Inst 2013; 105: 387-93.